Albertsons Companies (ACI) Earnings Date & Reports
Albertsons Companies Inc is a food and drug retailer in United States... Show more
ACI is expected to report earnings to rise 12.98% to 54 cents per share on July 28
Albertsons Companies (ACI) Fourth Quarter Fiscal 2025 Earnings Recap: Beat on Profits Amid Pharmacy Pressures
Key Takeaways
- Albertsons reported Q4 fiscal 2025 net sales and other revenue of $20.3 billion, up from $18.8 billion in the prior-year 12-week period, boosted by a 53rd week.
- Identical sales grew 0.7%, pressured by pharmacy headwinds from the Inflation Reduction Act (IRA, a U.S. law capping certain drug prices) and GLP-1 (glucagon-like peptide-1 drugs for diabetes/weight loss) mix shifts.
- Adjusted EBITDA reached $903 million, exceeding expectations despite challenges; full-year adjusted EBITDA hit $3.9 billion.
- Adjusted EPS was $0.48, beating consensus estimates of $0.43 by $0.05.
- Net loss of $481 million due to a $600 million opioid settlement charge; shares fell over 3% post-earnings.
- FY2026 guidance includes identical sales of 0%-1%, adjusted EBITDA of $3.85-$3.925 billion, and raised dividend plus $2 billion buyback authorization.
Earnings Context and Why It Matters
Albertsons Companies (ACI), one of the largest U.S. food and drug retailers with over 2,200 stores, faces intensifying competition from Walmart, Costco, and Amazon in groceries and pharmacy services. This Q4 fiscal 2025 report (ended February 28, 2026) caps a year of resilience amid macroeconomic pressures, digital acceleration, and regulatory changes like the IRA impacting reimbursements. Investors watch closely as pharmacy dynamics—now a key growth driver—shift, while identical sales trends signal consumer health. Strong adjusted profitability underscores operational efficiency, but the opioid settlement and guidance will shape views on capital returns and merger prospects in a consolidating industry.
Albertsons posted net sales and other revenue of $20.3 billion for the 13-week Q4 fiscal 2025, up from $18.8 billion in the prior-year 12-week quarter. The increase reflected about $1.4 billion from the extra 53rd week, alongside 0.7% identical sales growth. Digital sales rose 16%, but pharmacy sales faced greater-than-expected headwinds: roughly 105 basis points from IRA pricing and 40 basis points from GLP-1 moderation (total ~145 bps impact).
Adjusted EBITDA climbed to $903.4 million (including ~$68 million from the extra week), from $855.1 million last year, beating analyst forecasts. Adjusted net income was $252 million, or $0.48 per share, topping consensus of $0.43. GAAP results showed a net loss of $480.8 million, or ($0.94) per share, driven by a $599.8 million pre-tax opioid settlement charge. Full-year net sales hit $83.2 billion (up from $80.4 billion), with 2% identical sales growth and adjusted EBITDA of $3.9 billion.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
ACI shares dropped 3.03% to $16.34 on April 14, 2026, post-earnings, extending declines in after-hours and premarket trading. The selloff stemmed from revenue slightly missing some estimates (~$20.3B vs. $20.49B expected in spots), pharmacy pressures exceeding forecasts, and the opioid charge overshadowing beats on adjusted EPS and EBITDA. Sentiment turned cautious despite capital returns boosts—a 13% dividend hike to $0.17/share and $2B buyback reset—reflecting broader grocery sector woes like margin squeezes.
Forward Outlook and Key Factors to Monitor
Albertsons issued fiscal 2026 guidance (53-week year ending ~Feb 2027) projecting identical sales growth of 0%-1% (1.5%-2.5% excluding IRA impacts), reflecting ongoing pharmacy reimbursement challenges and moderating GLP-1 demand.
Adjusted EBITDA is guided at $3.85-$3.925 billion, supported by a $2 billion three-year productivity program, AI/digital investments, and supply chain efficiencies. Adjusted EPS outlook is $2.22-$2.32, with capex at $2.0-$2.2 billion focused on remodels (94 completed in FY2025), new stores, and tech platforms. Effective tax rate: 24%-25%.
Investors should track pharmacy trends under IRA, digital/loyalty growth (49.8M members prior), fuel margins, and Own Brands performance amid inflation. Capital allocation remains key: FY2025 saw $1.8B+ returned via buybacks/dividends, with fresh authorization signaling confidence. Broader catalysts include potential M&A (mergers and acquisitions) in fragmented grocery, labor dynamics, and consumer spending resilience.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a company, which engages in production and distribution of thermal coal
Industry FoodRetail